Endoscopic balloon dilation of benign esophageal strictures in dogs and cats

Endoscopic balloon dilation of benign esophageal strictures was performed in 18 dogs and 10 cats with a median age of 4 years. Stricture formation was associated with a recent anesthetic episode in 18 patients. Regurgitation was the most common clinical sign and was present a median of 4 weeks before dilation. Most animals had a single stricture; median diameter was 5 mm, and median length was 1 cm. Esophagitis and mucosal fibrosis were detected in 9 patients each. Dilation was performed with progressively increasing diameter balloons, from 6 to 20 mm. After dilation, mucosal hemorrhage was mild to moderate in most patients. Esophageal perforation was the only serious complication and occurred in 1 patient. Postdilation therapy consisted of administration of cimetidine, metoclopramide, sucralfate, and prednisone in most animals. The median number of dilation procedures performed in each animal was 2, with a range of 1-5. The median interval between dilations was 13 days. Stricture diameter markedly increased with subsequent dilations. Median duration of follow-up was 131 weeks. A successful outcome occurred in 88% of patients, with most animals able to eat canned, mashed, or dry food without regurgitation. Mucosal fibrosis was associated with a better clinical response score, while increasing age was weakly associated with fewer dilations. The dilation protocol used in this group of animals was safe and efficacious.     

Kepone effects on larval development of mud-crab and blue-crab

Laboratory experiments wer conducted to determine the effects of Kepone on the larval development of the mud-crab,Rhithropanopeus harrisii, and the commercial blue crab,Callinectes sapidus, from the time of hatching until the 1st crab stage was reached. Differential survival ofR. harrisii from hatching to 1st crab stage occurred in a range of 35 to 125 ppb Kepone, whereas differential survival ofC. sapidus over the same period of development occurred in a range of 0.1 to 1.0 ppb. Statistical analysis indicated that, for every 10 ppb Kepone added, duration from hatching to 1st crab stage ofR. harrisii was increased by 0.391±0.043 days; whereas for each increase of 0.1 ppb, the duration from hatching to 1st crab stage ofC. sapidus is prolonged by 0.38±0.10 days. The 1st and 2nd zoeal stages ofR. harrisii were the most sensitive developmental stages to Kepone, but the 1st zoeal stage ofC. sapidus was not sensitive, statistically, to any concentration of Kepone tested. In zoeal stages II, III and IV, there were significant increases in mortality ofC. sapidus over the previous stage in all media tested.     

Effects of hexavalent chromium on development of crabs,Rhithropanopeus harrisii and Callinectes sapidus

Survival of Rhithropanopeus harrisii larvae from hatching to first crab stage occurred in Na₂CrO₄ concentrations from 1.1 to 29.1 ppm. Estimated LC50 for complete zoeal development was 17.8 ppm Na₂CrO₄ and it was 13.7 ppm for development to first crab stage. A concentration of 1.1 ppm Na₂CrO₄ was nontoxic, while Na₂CrO₄ concentrations of 7.2 and 14.5 ppm were sublethal and concentrations of 29.1 to 58.1 ppm were acutely toxic. Low concentrations of Na₂Cr0₄ caused an increase in swimming speed and high concentrations caused a decline. Survival of Callinectes sapidus larvae occurred in Na₂CrO₄ concentrations from 1.1 to 4.7 ppm. The LC50 for complete zoeal development was estimated to be 2.9 ppm Na₂CrO₄ and the LC50 for development to first crab stage was estimated to be 1.0 ppm Na₂CrO₄ The total Cr in sodium chromate is 32% by weight (Tacey,1981), hence, the total Cr concentrations tested were 32% of the Cr salts given above. Statistical analyses of the data on survival, duration and mortality of larvae are presented.     

Clinical management of a western lowland gorilla (Gorilla gorilla gorilla) with a cardiac resynchronization therapy device

A 24-yr-old, male western lowland gorilla (Gorilla gorilla gorilla) was diagnosed with congestive heart failure using transesophageal and transthoracic echocardiology. New York Heart Association (NYHA) Class III was assigned to the severity of the condition. Over 16 mo, this progressed to NYHA Class IV despite increasing medical therapy. Repeated evaluations suggested that implantation of a cardiac resynchronization therapy device with a defibrillator (CRT-D) could benefit this animal based on clinical signs and underlying evidence of dyssynchrony and suspected fibrotic myocardial disease. Surgical implantation of leads into the right atrium, right ventricle, and left ventricle was accomplished. The CRT-D device was placed under the thoracic pectoral muscles during an initial surgical procedure. Improvement in the gorilla's clinical condition after implantation of the CRT-D device was immediate and dramatic. Subsequent scanning of the device was accomplished through operant conditioning. The data from these device interrogations included stored and real-time cardiac data, which were used to minimize recognized environmental stressors and change device settings. Over 4 yr, case management was critical to successful device use in treatment of the clinical disease. This involved medications, training for device interrogation, exercise to increase activity and improve body condition, and phlebotomy attempts. Dietary management was necessary to manipulate caloric and sodium intake and encourage medication compliance. Cardiac resynchronization therapy device implantation, although requiring specialized equipment and surgical skill, appears to be a viable option for treatment of fibrosing cardiomyopathy with systolic dysfunction in gorillas refractory to medical management. In addition to treatment, this device provides cardiovascular data at rest that could allow for early diagnosis and treatment of gorillas with this and other cardiac conditions in the future. This describes the comprehensive medical, husbandry, and training techniques necessary to successfully manage this intense clinical case in conjunction with intracardiac device therapy.     

Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs

The objective of this study was to evaluate the safety and efficacy of a purified porcine insulin zinc suspension for treating dogs with uncomplicated diabetes mellitus. Fifty-three dogs were treated for 60 days after an initial dose determination period. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs were determined before beginning insulin therapy (time 0), at the end of the dose determination period (time 1), 30 days after time 1 (time 2), and 60 days after time 1 (time 3). Presence of polyuria, polydipsia, and ketonuria was determined at each time point. Adequacy of control of hyperglycemia was based on 12-hour blood glucose curves and improvement in clinical variables (results of physical examinations, historic information, polyuria, polydipsia, and ketonuria). Safety was evaluated by questionnaire, performance of physical examination, CBC, serum chemistry profile, and urinalysis. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs at times 1, 2, and 3 were significantly lower compared with time 0 (P < .0001). There was a reduction in the proportion of dogs with polyuria, polydipsia, and ketonuria of 82, 86, and 80%, respectively. All of the dogs had adequate glycemic control at time 1, 66% at time 2, and 75% at time 3. At time 3, 66% of dogs required insulin injections q12h. Other than hypoglycemia, there were no important adverse effects of insulin administration. The insulin, was safe and efficacious for reducing blood glucose and clinical signs in dogs with diabetes mellitus.